ArticleAsian Pacific journal of cancer prevention : APJCP2026
The Clinical Relevance and Prognostic Significance of Calcitonin Receptor-Like (CALCRL) Gene Expression in AML Patients.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of the key immune and inflammatory related gene CALCRL as diagnostic biomarker in differentiating uterine leiomyosarcoma from leiomyoma.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outcome of acute myeloid leukemia (AML) is heterogeneous, with both patient-related and disease-related factors contributing to an individual patient's likelihood of achieving a therapeutic response and survival. The Calcitonin Receptor-Like (CALCRL) gene, which encodes the calcitonin receptor-like receptor, has emerged as a point of interest in studying AML. Its expression levels may hold clinical relevance and contribute to the prognostic assessment of AML patients. In the current study, we evaluated CALCRL gene expression levels to verify their possible association with the clinical and laboratory characteristics of AML and to clarify its potential role as a molecular prognostic marker in a cohort of Egyptian AML patients.
methodsCALCRL gene expression was estimated in 80 newly diagnosed adult Egyptian AML patients by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR).
resultsCALCRL gene expression in AML cases ranged from 0.11 to 104.11, with a median value of 2.1. It was higher in AML cases compared to controls; however, the difference was not statistically significant. AML cases were stratified into high and low CALCRL expression groups. Overall survival (OS) was higher in CALCRL-low compared to CALCRL-high expressers, yet the difference was not statistically significant. There was no statistical difference between CALCRL-high and CALCRL-low expressers regarding their complete remission rate (CR) and relapse-free survival (RFS). However, the incidence of relapse was higher in CALCRL-low expressers. In our study, the median age of the AML cases was 43 years. OS was significantly longer in CALCRL-low expressers, while RFS was significantly longer in CALCRL-high expressers younger than 43 years old.
conclusionStudying CALCRL gene expression in larger cohorts and over longer follow-up periods is highly recommended to gain deeper insight into its functional role in oncogenesis and chemoresistance, as well as its potential as a molecular prognostic marker and future therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.